Question

Is stem cell therapy for Diabetes (Type 1 & 2) covered by insurance?

Coverage depends on product, indication, country and policy. Obtain a written eligibility and coverage decision for the exact authorised treatment or trial, including immunosuppression, monitoring and complications; do not infer it from coverage of insulin.

Medical review statusPending clinical sign-offLast evidence update: 2026-08-05Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The cost picture for Diabetes (Type 1 & 2)

Costs cannot be generalised across routine diabetes care, authorised islet transplantation and investigational cell products. Obtain an itemised estimate for assessment, product, procedure, immunosuppression where applicable, monitoring, travel and complication care. Do not interrupt insulin or other established treatment because an experimental programme is being considered.

Am I a candidate? → · Diabetes (Type 1 & 2): full overview → · Diabetes (Type 1 & 2) cost → · Cost →

Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.

Sources & further reading

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information